Physician-reviewed · Evidence-based · Updated April 2026
Semaglutide, tirzepatide, and liraglutide. Real incidence numbers, real timelines, and a comparison with the medications you already take.
Quick answer
The most common GLP-1 side effects are nausea (44% on semaglutide), diarrhoea (30%), vomiting (24%), and constipation (24%). These are gastrointestinal effects from slowed stomach emptying. They peak in the first 2 to 4 weeks at each new dose and improve over 4 to 8 weeks. Serious side effects are rare. Pancreatitis affects roughly 0.3% of users. Use the four categories below to know whether to manage at home, call your doctor, or seek emergency care today.
Expected
5 effects
Common, mild, and self-limiting. Manage at home with simple steps.
Monitor
6 effects
Track frequency and severity. Tell your physician at the next visit.
Call Doctor
6 effects
Contact your physician today. Do not wait for the next appointment.
Urgent Care
1 effect
Stop the medication and call 112 or go to the nearest emergency room.
The common side effects
These are the gastrointestinal and general effects reported by at least 1 in 14 people in the major obesity trials. Most are dose-dependent and improve as your body adjusts. The bar shows the percentage of patients on semaglutide who reported each effect in STEP-1.
Onset: day 3 · Improves by: week 4
Nausea is the most common side effect and usually peaks in the first 2 to 4 weeks at each new dose, then improves. It affects about 44 out of 100 people on semaglutide but typically does not cause stopping the medication.
Worsened by:
Improved by:
Onset: day 5 · Improves by: week 3
Vomiting happens in about 1 in 4 people on semaglutide and is less common with tirzepatide. It almost always improves within a few weeks as your body adjusts to the medication.
Worsened by:
Improved by:
Onset: day 7 · Improves by: week 6
About 1 in 3 people experience diarrhoea, especially in the early weeks. Staying well hydrated is the most important management step. Dehydration is a real risk.
Worsened by:
Improved by:
Onset: day 14 · Improves by: week 8
Constipation is more persistent than nausea and can last for months on GLP-1 therapy because the medication slows digestion. Proactive hydration and fibre intake prevent most severe cases.
Worsened by:
Improved by:
Onset: day 4 · Improves by: week 4
Mild abdominal cramping and bloating are common. Severe or persistent pain that radiates to your back is a warning sign requiring immediate medical attention.
Worsened by:
Improved by:
Onset: day 10 · Improves by: week 6
Heartburn and indigestion occur in about 1 in 10 people. This happens because GLP-1 slows stomach emptying, and acid has more time to irritate the oesophagus.
Worsened by:
Improved by:
Onset: day 7 · Improves by: week 6
Fatigue in the early weeks is partly from reduced calorie intake and partly from the medication. It usually improves as your body adapts. Ensure you are eating adequate protein.
Worsened by:
Improved by:
Onset: day 7 · Improves by: week 4
Headaches are common in the first few weeks and are often related to changes in eating patterns and mild dehydration rather than the drug itself.
Worsened by:
Improved by:
Timeline
Most gastrointestinal effects intensify in the first 2 to 4 weeks of each new dose, then improve. Constipation is the exception. It tends to persist for as long as treatment continues, which is why proactive fibre and hydration matter from week one.
Bars show typical duration of each effect on semaglutide 2.4mg weekly. Coloured blocks mark the peak week. Source: STEP-1 NEJM 2021 and FDA Wegovy label 2023.
Serious side effects
These effects are rare but require active recognition because early action changes outcomes. Each card shows the red-flag warning sign in a high-visibility band so you can spot it without expanding the section. The expandable details give the full incidence, source, and clinical context.
Pancreatitis is a rare but serious condition affecting about 3 in 1,000 people on GLP-1 therapy. The key warning sign is severe abdominal pain that radiates to your back and does not improve. This requires immediate emergency care.
Semaglutide incidence: 0.3%
Tirzepatide incidence: 0.2%
Source: FDA Saxenda label 2023; MHRA 2026 strengthened pancreatitis warning
Gallstone risk is about 3 to 5 times higher than placebo, likely because rapid weight loss concentrates bile. Eating a small amount of fat at each meal (a teaspoon of oil, a handful of nuts) significantly reduces this risk.
Semaglutide incidence: 2.5%
Tirzepatide incidence: 1.2%
Source: Wilding JPH et al. STEP-1 NEJM 2021; FDA Wegovy label 2023
Kidney injury from GLP-1 is almost always caused by severe dehydration from vomiting or diarrhoea, not the medication itself. Staying well hydrated is the most effective prevention.
Semaglutide incidence: 0.5%
Tirzepatide incidence: 0.4%
Source: FDA Wegovy label 2023; FDA class labeling update 2023
GLP-1 medications carry a boxed warning about a rare type of thyroid cancer (MTC) found in animal studies. No human cases have been confirmed as caused by GLP-1 drugs. However, if you have a personal or family history of MTC or MEN2, these medications should not be used.
Source: FDA Wegovy Boxed Warning 2023; FDA Zepbound label 2024; Bjerre Knudsen L et al.
True gastroparesis (stomach paralysis) from GLP-1 is rare. The medication is designed to slow stomach emptying for appetite control. In most people this is mild and beneficial.
Semaglutide incidence: 0.2%
Tirzepatide incidence: 0.1%
Source: FDA safety communication April 2024; Sodhi et al. JAMA 2023
GLP-1 medications slow stomach emptying, which increases the risk of inhaling stomach contents during general anaesthesia. Always tell your surgeon and anaesthetist you are taking GLP-1 medication. Most guidelines recommend stopping at least 1 week before any elective surgery.
Source: Silveira SQ et al. 2025 systematic review; ASA guidance 2024; MHRA 2024
GLP-1 medications are glucose-dependent and rarely cause hypoglycaemia on their own. The risk is significant only when combined with insulin or sulfonylurea diabetes tablets. If you take those, discuss dose adjustment with your physician before starting GLP-1.
Semaglutide incidence: 1%
Tirzepatide incidence: 2%
Source: FDA Wegovy label 2023; SURMOUNT-1 2023
In patients with type 2 diabetes and pre-existing retinopathy, rapid improvement in blood sugar can paradoxically worsen retinal changes in the short term. This is most relevant for diabetic patients, not those using GLP-1 only for weight loss.
Semaglutide incidence: 2.7%
Source: Marso SP et al. SUSTAIN-6 NEJM 2016; FDA Ozempic label note
Tool 1
Answer 6 short questions about your health. The tool returns a tolerability score, a benefit score, the most likely side effects for your profile, and 5 specific questions to take to your physician.
Comparison layer
The honest comparison matters because side effect numbers in isolation feel alarming. Azithromycin causes nausea in 18% of users and diarrhoea in 14% over a 5-day course. Metformin causes GI side effects in 25 to 30% of users and is taken lifelong. Escitalopram causes sexual dysfunction in up to 70% of users. The key difference is that GLP-1 GI effects almost always improve over time. Some comparison medication effects (SSRI sexual dysfunction, ACE inhibitor cough) are often permanent.
| Medication | Indication | Nausea % | Any GI % | Serious AE % | Stop at 1 yr % | Weight effect | CV benefit |
|---|---|---|---|---|---|---|---|
| GLP-1 (Semaglutide 2.4mg) | Obesity, type 2 diabetes | 44% | 60% | 0.3% | 7% | Significant loss | Strong benefit |
| Metformin | Type 2 diabetes (first-line) | 25% | 30% | 0.003% | 20% | Mild loss | Moderate benefit |
| Atorvastatin (Lipitor) | High cholesterol, cardiovascular prevention | 4% | 10% | 0.1% | 30% | Neutral | Strong benefit |
| Amoxicillin | Bacterial infections (short course) | 15% | 30% | 0.5% | 5% | Neutral | None established |
| Azithromycin (Z-Pack) | Respiratory/bacterial infections (5 days) | 18% | 35% | 0.3% | 3% | Neutral | None established |
| Lisinopril | High blood pressure, heart failure | 2% | 5% | 0.3% | 15% | Neutral | Strong benefit |
| Escitalopram (SSRI) | Depression, anxiety disorders | 18% | 20% | 0.5% | 15% | Mild gain | None established |
| Omeprazole (PPI) | Acid reflux, stomach ulcers | 4% | 12% | 0.2% | 10% | Neutral | None established |
All percentages from FDA prescribing information and Cochrane reviews. Comparator data not adjusted for treatment duration.
Tool 2
Pick a GLP-1 medication and a comparator from your medicine cabinet. The tool shows nausea rate, GI disruption rate, serious adverse event rate, weight effect, and cardiovascular benefit side by side.
Select a familiar medication and a side effect dimension to compare.
GLP-1 causes nausea more often than Metformin, but GLP-1 nausea typically peaks in weeks 2 to 4 and then improves. Metformin side effects often persist for the duration of use.
Source: FDA prescribing labels; STEP-1, SURMOUNT-1, SCALE trials
Individual results may vary. This comparison is for educational purposes. Direct drug-to-drug comparisons have limitations as trials differ in design, population, and duration.
Tool 3
Describe what you are feeling. The tool returns one of four actions: manage at home, monitor closely, call your doctor today, or seek emergency care now. This is not a substitute for medical advice.
Select your symptom. Results update instantly.
Do you have any of these symptoms right now?
After stopping
The single most important question to ask before starting GLP-1 is: what happens when I stop. The STEP-1 extension and SURMOUNT-4 trials answer this directly. Both medications produce significant weight loss while taken. Both also show substantial weight regain within one year of discontinuation, with roughly two-thirds of the lost weight returning. New 2026 data from Washington University shows a 22% increase in major adverse cardiovascular events in semaglutide users who discontinue compared with those who stay on therapy. This makes GLP-1 a long-term medical therapy in the same category as antihypertensives and statins.
Source: Wilding JPH et al. NEJM 2022; SURMOUNT-4; Washington Univ 2026; Aronne LJ et al. SURMOUNT-4 2024.
Physician review
Internal Medicine. Co-founder, DermaVue Clinics. Obesity Medicine.
Dr. Rejeesh trained in internal medicine in the United States and has supervised over 1,200 GLP-1 patients across DermaVue Kerala and Tamil Nadu. He reviewed every clinical figure on this page against the underlying FDA labels and randomised trial publications. Last review: 7 April 2026.
Frequently asked
The most common GLP-1 side effects are nausea (44% on semaglutide), diarrhoea (30%), vomiting (24%), and constipation (24%). These are gastrointestinal effects caused by the medication slowing stomach emptying. They are most pronounced during dose escalation and typically improve over 4 to 8 weeks. Tirzepatide has a similar but generally milder GI profile, with nausea affecting around 31% of patients.
Most GLP-1 side effects, especially nausea and vomiting, peak during the first 2 to 4 weeks at each new dose and then gradually improve. By 8 to 12 weeks at a stable dose, most patients find GI side effects have reduced significantly or resolved. Constipation tends to be more persistent and may last as long as treatment continues. Serious side effects like pancreatitis or gallbladder disease do not resolve without medical treatment.
GLP-1 medications cause more nausea (44%) than most familiar medications, but this should be understood in context. Azithromycin (Z-Pack) causes nausea in 18% and diarrhoea in 14% of users over just 5 days. Metformin causes GI side effects in 25 to 30% of users and is prescribed lifelong. Escitalopram causes sexual dysfunction in up to 70% of users. The key difference is that GLP-1 GI side effects almost always improve over time, while some comparison medication effects (sexual dysfunction from SSRIs, dry cough from ACE inhibitors) are often persistent.
Acute pancreatitis occurs in approximately 0.3% of patients on semaglutide, about 3 in every 1,000 people. The key warning sign is severe abdominal pain, especially pain that radiates to your back and does not improve with position changes. This requires immediate emergency care. Do not wait for a scheduled appointment. The MHRA strengthened its pancreatitis warning for GLP-1 medications in 2026.
All GLP-1 medications carry a boxed warning about medullary thyroid carcinoma (MTC) based on studies in rats. No human cases of thyroid cancer caused by GLP-1 medications have been confirmed. However, GLP-1 medications are contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2). If you notice a new neck lump, difficulty swallowing, or hoarseness while on GLP-1, report this to your physician.
Yes. GI side effects (nausea, vomiting, diarrhoea, constipation) resolve within days to weeks of stopping GLP-1 medication. Injection site reactions also resolve quickly. Serious complications like gallstones, once formed, may require treatment regardless of whether you continue the medication. The weight loss benefit also reverses after stopping: clinical trial data shows about two-thirds of weight lost is regained within one year of discontinuation.
Seek emergency care immediately (call 112 in India) for: severe abdominal pain radiating to the back (possible pancreatitis), inability to keep any fluids down for more than 24 hours, right upper quadrant pain with fever or jaundice (possible gallbladder emergency), fainting or near-fainting (dehydration or hypoglycaemia), or sudden vision changes. Stop your GLP-1 medication immediately if any of these occur.
For most patients who persist through the initial 4 to 8 weeks, GLP-1 therapy produces 15 to 21% body weight loss, significant cardiovascular risk reduction, and meaningful metabolic improvement. Clinical trial dropout rates due to side effects are around 5 to 7%, meaning over 90% of patients in trials manage the side effects successfully. The key is proactive management: small frequent low-fat meals, excellent hydration, and slow dose escalation. Whether the benefits are worth it for you personally depends on your health goals and context. A physician consultation can help you weigh this.
Always tell your surgeon, anaesthetist, and any doctor involved in your procedure that you are taking a GLP-1 medication. GLP-1 slows stomach emptying significantly, increasing the risk of inhaling stomach contents during general anaesthesia. Most clinical guidelines recommend stopping GLP-1 medication at least 1 week before any elective surgery. Your anaesthetist may also require extended fasting beyond the standard nil-by-mouth period.
Several important drug interactions apply. Insulin and sulfonylurea (glimepiride, glipizide): GLP-1 significantly increases hypoglycaemia risk and dose reduction is usually required. Tirzepatide and oral contraceptives: tirzepatide reduces contraceptive pill absorption by 59% and additional barrier contraception is needed during initiation and at every dose escalation. Warfarin users: more frequent INR monitoring during titration. Levothyroxine: take thyroid medication consistently on an empty stomach as GLP-1 may affect absorption timing.
Next step
A 30-minute consultation at any DermaVue clinic in Kerala or Tamil Nadu covers your eligibility, medication options, expected side effects for your specific health profile, and the realistic monthly cost. Dr. Rejeesh M. Menon and the DermaVue medical team have supervised over 1,200 GLP-1 patients to date.